BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25190012)

  • 1. Analysis of biological therapeutic agents and biosimilars.
    Phinney K
    Anal Bioanal Chem; 2014 Oct; 406(26):6539. PubMed ID: 25190012
    [No Abstract]   [Full Text] [Related]  

  • 2. Differences in bioanalytical method validation for biologically derived macromolecules (biosimilars) compared with small molecules (generics).
    Oldfield P
    Bioanalysis; 2011 Jul; 3(14):1551-3. PubMed ID: 21756087
    [No Abstract]   [Full Text] [Related]  

  • 3. Analytical Aspects of Biopharmaceuticals and their Study by Mass Spectrometry.
    David V; Borbala D; Laroly V; Laszlo D; Istvan A; Imre K; Krisztina L
    Acta Pharm Hung; 2016; 86(4):141-150. PubMed ID: 29870600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A wide angle view of biosimilars from a bioanalytical perspective.
    Oldfield P
    Bioanalysis; 2013 Mar; 5(5):533-5. PubMed ID: 23425269
    [No Abstract]   [Full Text] [Related]  

  • 5. Bioanalytical challenges of biosimilars.
    Islam R
    Bioanalysis; 2014 Feb; 6(3):349-56. PubMed ID: 24471955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development.
    Cai XY; Wake A; Gouty D
    Bioanalysis; 2013 Mar; 5(5):517-20. PubMed ID: 23425265
    [No Abstract]   [Full Text] [Related]  

  • 7. Nonclinical development of a biosimilar: the current landscape.
    O'Connor A; Rogge M
    Bioanalysis; 2013 Mar; 5(5):537-44. PubMed ID: 23425270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Particle sizing methods for the detection of protein aggregates in biopharmaceuticals.
    Khodabandehloo A; Chen DD
    Bioanalysis; 2017 Feb; 9(3):313-326. PubMed ID: 28098491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conference Report: Bioanalysis-related topics presented at the International Conference and Exhibition on Biowaivers and Biosimilars.
    Colletti KS
    Bioanalysis; 2013 Mar; 5(5):529-31. PubMed ID: 23425268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in bioanalytical assays for biosimilars.
    Wang X; Chen L
    Bioanalysis; 2014 Aug; 6(16):2111-3. PubMed ID: 25331854
    [No Abstract]   [Full Text] [Related]  

  • 11. Mini Focus: bioanalysis of biosimilars.
    Amaravadi L; Marini J
    Bioanalysis; 2013 Mar; 5(5):515-6. PubMed ID: 23425264
    [No Abstract]   [Full Text] [Related]  

  • 12. Application of the parallel line assay to assessment of biosimilar products based on binary endpoints.
    Lin JR; Chow SC; Chang CH; Lin YC; Liu JP
    Stat Med; 2013 Feb; 32(3):449-61. PubMed ID: 22911920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European perspective on biosimilars.
    Wadhwa M; Thorpe R
    Bioanalysis; 2013 Mar; 5(5):521-4. PubMed ID: 23425266
    [No Abstract]   [Full Text] [Related]  

  • 14. An adapted F-test for homogeneity of variability in follow-on biological products.
    Yang J; Zhang N; Chow SC; Chi E
    Stat Med; 2013 Feb; 32(3):415-23. PubMed ID: 22933180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quotient Bioresearch complete £1.5 million expansion of bioanalytical research facilities.
    King G
    Bioanalysis; 2012 Nov; 4(22):2666. PubMed ID: 23346559
    [No Abstract]   [Full Text] [Related]  

  • 16. Biosimilars and reference biologics: decisions on biosimilar interchangeability require the involvement of dermatologists.
    Puig L
    Actas Dermosifiliogr; 2014 Jun; 105(5):435-7. PubMed ID: 24094515
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial for the special issue titled "Biopharmaceuticals 2020".
    Fekete S; Guillarme D
    J Pharm Biomed Anal; 2020 May; 183():113198. PubMed ID: 32113748
    [No Abstract]   [Full Text] [Related]  

  • 18. Biosimilars: the 'future' of biologic therapy?
    Ranjan N; Mahajan VK; Misra M
    J Dermatolog Treat; 2011 Dec; 22(6):319-22. PubMed ID: 20666673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development of biosimilars: an evolving landscape.
    Subramanyam M
    Bioanalysis; 2013 Mar; 5(5):575-86. PubMed ID: 23425273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Perspectives on Ligand-Binding Assay Practices in the Quantification of Circulating Therapeutic Proteins for Biosimilar Biological Product Development.
    Thway TM; Wang YM; Booth BP; Maxfield K; Huang SM; Zineh I
    AAPS J; 2019 Dec; 22(1):15. PubMed ID: 31858313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.